AG˹ٷ

STOCK TITAN

[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

ChargePoint Holdings, Inc. (NYSE: CHPT) filed an 8-K covering board and corporate actions taken between 7-7-2025 and 7-9-2025.

Key personnel change: Chief Legal Officer & Corporate Secretary Rebecca Chavez will resign effective July 25, 2025 to pursue another opportunity.

2025 Annual Meeting results (58.6 % quorum):

  • Four Class II directors were re-elected to serve until 2028.
  • PWC ratified as independent auditor for FY 2026.
  • Advisory “say-on-pay� passed (80.3 m for vs. 15.2 m against).
  • Reverse Stock Split amendment approved (232.9 m for, 34.1 m against) allowing a split ratio between 1-for-2 and 1-for-30.
  • Corporate Opportunity Waiver amendment failed.
  • Adjournment authority approved.

Reverse stock split executed: On July 9, 2025 the Nominating & Governance Committee set the ratio at 1-for-20, effective 12:01 a.m. ET on July 28 2025. Outstanding shares will drop from ~467.1 million to ~23.4 million; equity awards, warrants and convertible notes will be proportionally adjusted. No fractional shares will be issued; cash will be paid in lieu. The action targets regaining NYSE compliance after falling below the US$1.00 minimum price in February 2025. Trading symbol remains CHPT; new CUSIP 15961R 303.

Material implications for investors:

  • The split should immediately lift the per-share price and preserve the NYSE listing, but it does not improve underlying fundamentals.
  • Share count reduction may increase per-share metrics (EPS, book value) mechanically, with no change in proportional ownership.
  • Departure of the CLO introduces near-term succession and governance risk.
  • Failure of the corporate opportunity waiver suggests some shareholder concern over governance amendments.

ChargePoint Holdings, Inc. (NYSE: CHPT) ha depositato un modulo 8-K riguardante le azioni del consiglio e societarie adottate tra il 7 e il 9 luglio 2025.

Cambio di personale chiave: Rebecca Chavez, Chief Legal Officer e Corporate Secretary, si dimetterà a partire dal 25 luglio 2025 per intraprendere un'altra opportunità lavorativa.

Risultati dell'Assemblea Annuale 2025 (quorum 58,6%):

  • Quattro direttori di Classe II sono stati rieletti fino al 2028.
  • PWC è stata ratificata come revisore indipendente per l'esercizio 2026.
  • Approvato l'advisory “say-on-pay� (80,3 milioni favorevoli contro 15,2 milioni contrari).
  • Approvata la modifica per lo Split Azionario Inverso (232,9 milioni favorevoli, 34,1 milioni contrari) che consente un rapporto di frazionamento tra 1-per-2 e 1-per-30.
  • La modifica per la deroga sulle opportunità societarie non è stata approvata.
  • Approvata l'autorità di rinvio dell'assemblea.

Split azionario inverso eseguito: Il 9 luglio 2025 il Comitato per la Nomina e la Governance ha fissato il rapporto a 1-per-20, con efficacia dalle 00:01 ET del 28 luglio 2025. Le azioni in circolazione passeranno da circa 467,1 milioni a circa 23,4 milioni; premi azionari, warrant e note convertibili saranno adeguati proporzionalmente. Non saranno emesse azioni frazionarie; verrà corrisposto un importo in contanti in sostituzione. L'operazione mira a ristabilire la conformità con la NYSE dopo che il prezzo è sceso sotto 1,00 USD a febbraio 2025. Il simbolo di borsa rimane CHPT; nuovo CUSIP 15961R 303.

Implicazioni rilevanti per gli investitori:

  • Lo split dovrebbe aumentare immediatamente il prezzo per azione e preservare la quotazione NYSE, ma non migliora i fondamentali sottostanti.
  • La riduzione del numero di azioni può aumentare meccanicamente le metriche per azione (EPS, valore contabile) senza modificare la proprietà proporzionale.
  • La partenza del CLO introduce rischi di successione e governance nel breve termine.
  • Il mancato approvazione della deroga sulle opportunità societarie indica preoccupazioni da parte di alcuni azionisti sulle modifiche di governance.

ChargePoint Holdings, Inc. (NYSE: CHPT) presentó un formulario 8-K que cubre acciones del consejo y corporativas tomadas entre el 7 y el 9 de julio de 2025.

Cambio clave de personal: Rebecca Chavez, Chief Legal Officer y Secretaria Corporativa, renunciará con efecto el 25 de julio de 2025 para buscar otra oportunidad.

Resultados de la Junta Anual 2025 (quórum 58.6%):

  • Cuatro directores de Clase II fueron reelectos para servir hasta 2028.
  • PWC fue ratificada como auditor independiente para el año fiscal 2026.
  • Se aprobó la consulta consultiva “say-on-pay� (80.3 millones a favor vs. 15.2 millones en contra).
  • Aprobada la enmienda para la división inversa de acciones (232.9 millones a favor, 34.1 millones en contra) que permite una proporción entre 1-por-2 y 1-por-30.
  • La enmienda para la exención de oportunidades corporativas fue rechazada.
  • Se aprobó la autoridad para aplazar la reunión.

División inversa de acciones ejecutada: El 9 de julio de 2025, el Comité de Nominaciones y Gobernanza estableció la proporción en 1-por-20, con vigencia a las 12:01 a.m. ET del 28 de julio de 2025. Las acciones en circulación disminuirán de aproximadamente 467.1 millones a aproximadamente 23.4 millones; las concesiones de acciones, warrants y notas convertibles se ajustarán proporcionalmente. No se emitirán acciones fraccionarias; se pagará efectivo en su lugar. La acción tiene como objetivo recuperar el cumplimiento con la NYSE tras caer por debajo del precio mínimo de US$1.00 en febrero de 2025. El símbolo de cotización permanece CHPT; nuevo CUSIP 15961R 303.

Implicaciones importantes para los inversores:

  • La división debería aumentar inmediatamente el precio por acción y preservar la cotización en NYSE, pero no mejora los fundamentos subyacentes.
  • La reducción del número de acciones puede aumentar mecánicamente las métricas por acción (EPS, valor contable) sin cambiar la propiedad proporcional.
  • La salida del CLO introduce riesgos de sucesión y gobernanza a corto plazo.
  • El rechazo de la exención de oportunidades corporativas sugiere cierta preocupación de los accionistas sobre las enmiendas de gobernanza.

ChargePoint Holdings, Inc. (NYSE: CHPT)� 2025� 7� 7일부� 7� 9일까지 이사� � 회사 조치� 관� 8-K 보고서를 제출했습니다.

주요 인사 변�: 법률 최고 책임자이� 회사 비서� Rebecca Chavez가 2025� 7� 25일부� 다른 기회� 추구하기 위해 사임� 예정입니�.

2025� 연례 주주총회 결과 (58.6% 출석�):

  • 4명의 클래� II 이사가 2028년까지 재선임되었습니다.
  • 회계법인 PWC가 2026 회계연도 독립 감사인으� 재확정되었습니다.
  • 자문 “보� 승인(say-on-pay)� 안건� 통과되었습니� (찬성 8,030만표, 반대 1,520만표).
  • 역주식분� 수정� 승인 (찬성 2� 3,290만표, 반대 3,410만표) - 1대 2에서 1대 30 사이� 비율 허용.
  • 기업 기회 면제 수정안은 붶�되었습니�.
  • 회의 연기 권한 승인.

역주식분� 실행: 2025� 7� 9�, 지� � 거버넌스 위원회가 1대 20 비율� 결정했으�, 2025� 7� 28� 동부시간 00:01부� 효력� 발생합니�. 발행 주식 수는 � 4� 6,710� 주에� � 2,340� 주로 감소하며, 주식 보상, 워런� � 전환사채� 비례 조정됩니�. 분할 � 소수 주식은 발행하지 않고 현금으로 정산합니�. 이번 조치� 2025� 2� 주가가 미화 1.00달러 이하� 떨어� � NYSE 상장 요건� 회복하기 위한 것입니다. 거래 심볼은 CHPT� 유지되며, 새로� CUSIP은 15961R 303입니�.

투자자에 대� 주요 영향:

  • 주식 분할은 주당 가격을 즉시 상승시켜 NYSE 상장� 유지하는 � 도움� 되지�, 기본 펀더멘� 개선은 아닙니다.
  • 주식 � 감소� 주당 지�(EPS, 장부가�)� 기계적으� 증가시킬 � 있으�, 지� 비율은 변하지 않습니다.
  • CLO� 퇴임은 단기적인 승계 � 거버넌스 위험� 초래합니�.
  • 기업 기회 면제 붶결은 일부 주주가 거버넌스 수정안에 대� 우려� 표명했음� 시사합니�.

ChargePoint Holdings, Inc. (NYSE : CHPT) a déposé un formulaire 8-K couvrant les actions du conseil d'administration et de la société prises entre le 7 et le 9 juillet 2025.

Changement clé de personnel : Rebecca Chavez, Chief Legal Officer et Corporate Secretary, démissionnera à compter du 25 juillet 2025 pour poursuivre une autre opportunité.

Résultats de l'Assemblée Générale Annuelle 2025 (58,6 % de quorum) :

  • Quatre administrateurs de Classe II ont été réélus pour un mandat jusqu'en 2028.
  • PWC a été ratifiée en tant qu'auditeur indépendant pour l'exercice 2026.
  • Le vote consultatif « say-on-pay » a été approuvé (80,3 millions pour contre 15,2 millions contre).
  • Amendement sur le fractionnement inverse des actions approuvé (232,9 millions pour, 34,1 millions contre) permettant un ratio de fractionnement entre 1 pour 2 et 1 pour 30.
  • L'amendement sur la dérogation aux opportunités corporatives a édzé.
  • Autorisation de ajournement approuvée.

Fractionnement inverse des actions exécuté : Le 9 juillet 2025, le Comité de nomination et de gouvernance a fixé le ratio à 1 pour 20, effectif à 00h01 ET le 28 juillet 2025. Le nombre d'actions en circulation passera d'environ 467,1 millions à environ 23,4 millions ; les attributions d'actions, les bons de souscription et les billets convertibles seront ajustés proportionnellement. Aucune action fractionnaire ne sera émise ; un paiement en espèces sera effectué à la place. Cette mesure vise à retrouver la conformité avec le NYSE après être tombée en dessous du prix minimum de 1,00 USD en février 2025. Le symbole boursier reste CHPT ; nouveau CUSIP 15961R 303.

Implications importantes pour les investisseurs :

  • Le fractionnement devrait immédiatement augmenter le prix par action et préserver la cotation NYSE, mais il n'améliore pas les fondamentaux sous-jacents.
  • La réduction du nombre d'actions peut mécaniquement augmenter les indicateurs par action (BPA, valeur comptable) sans changer la propriété proportionnelle.
  • Le départ du CLO introduit un risque de succession et de gouvernance à court terme.
  • L'échec de la dérogation aux opportunités corporatives suggère certaines préoccupations des actionnaires concernant les amendements de gouvernance.

ChargePoint Holdings, Inc. (NYSE: CHPT) reichte ein 8-K ein, das Vorstandsbeschlüsse und unternehmerische Maßnahmen zwischen dem 7. und 9. Juli 2025 abdeckt.

Wichtige Personaländerung: Chief Legal Officer & Corporate Secretary Rebecca Chavez wird zum 25. Juli 2025 zurücktreten, um eine andere Gelegenheit wahrzunehmen.

Ergebnisse der Hauptversammlung 2025 (58,6 % Quorum):

  • Vier Class-II-Direktoren wurden bis 2028 wiedergewählt.
  • PWC als unabhängiger Abschlussprüfer für das Geschäftsjahr 2026 bestätigt.
  • Beratende „Say-on-Pay�-Abstimmung angenommen (80,3 Mio. dafür vs. 15,2 Mio. dagegen).
  • Änderung zur Umkehraktienzusammenlegung genehmigt (232,9 Mio. dafür, 34,1 Mio. dagegen), die eine Split-Quote zwischen 1:2 und 1:30 erlaubt.
  • Änderung zur Corporate Opportunity Waiver abgelehnt.
  • Vertagungsbefugnis genehmigt.

Umkehraktienzusammenlegung durchgeführt: Am 9. Juli 2025 legte der Nominierungs- und Governance-Ausschuss das Verhältnis auf 1:20 fest, wirksam ab 28. Juli 2025, 00:01 Uhr ET. Die ausstehenden Aktien reduzieren sich von ca. 467,1 Millionen auf ca. 23,4 Millionen; Aktienprämien, Warrants und Wandelanleihen werden proportional angepasst. Bruchstücke werden nicht ausgegeben; stattdessen wird Barzahlung geleistet. Die Maßnahme zielt darauf ab, die NYSE-Compliance wiederherzustellen, nachdem der Kurs im Februar 2025 unter die Mindestnotierung von 1,00 USD gefallen war. Das Handelssymbol bleibt CHPT; neue CUSIP 15961R 303.

Wesentliche Auswirkungen für Investoren:

  • Der Split sollte den Kurs sofort anheben und die NYSE-Notierung erhalten, verbessert jedoch nicht die zugrunde liegenden Fundamentaldaten.
  • Die Reduzierung der Aktienanzahl kann die Kennzahlen pro Aktie (EPS, Buchwert) mechanisch erhöhen, ohne die prozentuale Eigentümerschaft zu verändern.
  • Der Weggang des CLO bringt kurzfristige Nachfolge- und Governance-Risiken mit sich.
  • Die Ablehnung des Corporate Opportunity Waivers deutet auf Bedenken einiger Aktionäre hinsichtlich der Governance-Änderungen hin.
Positive
  • Reverse stock split approved and set at 1-for-20, preserving NYSE listing eligibility
  • Auditor (PwC) ratified and all Class II directors re-elected, ensuring board and audit continuity
Negative
  • Need for reverse split confirms shares traded below US$1, reflecting weakened market valuation
  • Chief Legal Officer & Corporate Secretary Rebecca Chavez resigns, creating leadership gap
  • Corporate Opportunity Waiver amendment failed, indicating shareholder governance concerns

Insights

TL;DR: Reverse split preserves listing; neutral fundamental impact, modest governance headwinds from CLO exit.

The 1-for-20 reverse split is primarily a compliance maneuver to avoid NYSE delisting after sub-US$1 trading. While it should raise the market price by a factor of 20, it neither affects enterprise value nor liquidity in any material way aside from a likely narrower retail float. Management avoided maximum dilution by picking a mid-range ratio rather than the higher 1-for-30 allowed. Director re-elections and auditor ratification remove immediate governance overhangs, yet the unexpected resignation of the Chief Legal Officer revives succession risk in a heavily regulated industry. The failed corporate-opportunity waiver shows modest shareholder push-back but is non-critical to operations. Overall, the filing is operationally neutral: it prevents a negative delisting catalyst but does not provide new growth drivers.

TL;DR: Governance picture mixed—key legal officer exits and proposal defeat offset routine board approvals.

The resignation of Ms. Chavez removes an experienced legal steward during a period of strategic repositioning, heightening compliance and litigation exposure until a successor is named. Although shareholders backed director nominees and executive pay, roughly 15 % voted against compensation, highlighting sensitivity to dilution and performance metrics. The defeat of the corporate-opportunity waiver signals investor reluctance to loosen fiduciary safeguards, a subtle win for minority holders. Adoption of the reverse split aligns with shareholder interest in maintaining liquidity via NYSE listing; however, repeated reliance on mechanical price fixes can erode confidence in long-term value creation. Net governance impact is modestly negative.

ChargePoint Holdings, Inc. (NYSE: CHPT) ha depositato un modulo 8-K riguardante le azioni del consiglio e societarie adottate tra il 7 e il 9 luglio 2025.

Cambio di personale chiave: Rebecca Chavez, Chief Legal Officer e Corporate Secretary, si dimetterà a partire dal 25 luglio 2025 per intraprendere un'altra opportunità lavorativa.

Risultati dell'Assemblea Annuale 2025 (quorum 58,6%):

  • Quattro direttori di Classe II sono stati rieletti fino al 2028.
  • PWC è stata ratificata come revisore indipendente per l'esercizio 2026.
  • Approvato l'advisory “say-on-pay� (80,3 milioni favorevoli contro 15,2 milioni contrari).
  • Approvata la modifica per lo Split Azionario Inverso (232,9 milioni favorevoli, 34,1 milioni contrari) che consente un rapporto di frazionamento tra 1-per-2 e 1-per-30.
  • La modifica per la deroga sulle opportunità societarie non è stata approvata.
  • Approvata l'autorità di rinvio dell'assemblea.

Split azionario inverso eseguito: Il 9 luglio 2025 il Comitato per la Nomina e la Governance ha fissato il rapporto a 1-per-20, con efficacia dalle 00:01 ET del 28 luglio 2025. Le azioni in circolazione passeranno da circa 467,1 milioni a circa 23,4 milioni; premi azionari, warrant e note convertibili saranno adeguati proporzionalmente. Non saranno emesse azioni frazionarie; verrà corrisposto un importo in contanti in sostituzione. L'operazione mira a ristabilire la conformità con la NYSE dopo che il prezzo è sceso sotto 1,00 USD a febbraio 2025. Il simbolo di borsa rimane CHPT; nuovo CUSIP 15961R 303.

Implicazioni rilevanti per gli investitori:

  • Lo split dovrebbe aumentare immediatamente il prezzo per azione e preservare la quotazione NYSE, ma non migliora i fondamentali sottostanti.
  • La riduzione del numero di azioni può aumentare meccanicamente le metriche per azione (EPS, valore contabile) senza modificare la proprietà proporzionale.
  • La partenza del CLO introduce rischi di successione e governance nel breve termine.
  • Il mancato approvazione della deroga sulle opportunità societarie indica preoccupazioni da parte di alcuni azionisti sulle modifiche di governance.

ChargePoint Holdings, Inc. (NYSE: CHPT) presentó un formulario 8-K que cubre acciones del consejo y corporativas tomadas entre el 7 y el 9 de julio de 2025.

Cambio clave de personal: Rebecca Chavez, Chief Legal Officer y Secretaria Corporativa, renunciará con efecto el 25 de julio de 2025 para buscar otra oportunidad.

Resultados de la Junta Anual 2025 (quórum 58.6%):

  • Cuatro directores de Clase II fueron reelectos para servir hasta 2028.
  • PWC fue ratificada como auditor independiente para el año fiscal 2026.
  • Se aprobó la consulta consultiva “say-on-pay� (80.3 millones a favor vs. 15.2 millones en contra).
  • Aprobada la enmienda para la división inversa de acciones (232.9 millones a favor, 34.1 millones en contra) que permite una proporción entre 1-por-2 y 1-por-30.
  • La enmienda para la exención de oportunidades corporativas fue rechazada.
  • Se aprobó la autoridad para aplazar la reunión.

División inversa de acciones ejecutada: El 9 de julio de 2025, el Comité de Nominaciones y Gobernanza estableció la proporción en 1-por-20, con vigencia a las 12:01 a.m. ET del 28 de julio de 2025. Las acciones en circulación disminuirán de aproximadamente 467.1 millones a aproximadamente 23.4 millones; las concesiones de acciones, warrants y notas convertibles se ajustarán proporcionalmente. No se emitirán acciones fraccionarias; se pagará efectivo en su lugar. La acción tiene como objetivo recuperar el cumplimiento con la NYSE tras caer por debajo del precio mínimo de US$1.00 en febrero de 2025. El símbolo de cotización permanece CHPT; nuevo CUSIP 15961R 303.

Implicaciones importantes para los inversores:

  • La división debería aumentar inmediatamente el precio por acción y preservar la cotización en NYSE, pero no mejora los fundamentos subyacentes.
  • La reducción del número de acciones puede aumentar mecánicamente las métricas por acción (EPS, valor contable) sin cambiar la propiedad proporcional.
  • La salida del CLO introduce riesgos de sucesión y gobernanza a corto plazo.
  • El rechazo de la exención de oportunidades corporativas sugiere cierta preocupación de los accionistas sobre las enmiendas de gobernanza.

ChargePoint Holdings, Inc. (NYSE: CHPT)� 2025� 7� 7일부� 7� 9일까지 이사� � 회사 조치� 관� 8-K 보고서를 제출했습니다.

주요 인사 변�: 법률 최고 책임자이� 회사 비서� Rebecca Chavez가 2025� 7� 25일부� 다른 기회� 추구하기 위해 사임� 예정입니�.

2025� 연례 주주총회 결과 (58.6% 출석�):

  • 4명의 클래� II 이사가 2028년까지 재선임되었습니다.
  • 회계법인 PWC가 2026 회계연도 독립 감사인으� 재확정되었습니다.
  • 자문 “보� 승인(say-on-pay)� 안건� 통과되었습니� (찬성 8,030만표, 반대 1,520만표).
  • 역주식분� 수정� 승인 (찬성 2� 3,290만표, 반대 3,410만표) - 1대 2에서 1대 30 사이� 비율 허용.
  • 기업 기회 면제 수정안은 붶�되었습니�.
  • 회의 연기 권한 승인.

역주식분� 실행: 2025� 7� 9�, 지� � 거버넌스 위원회가 1대 20 비율� 결정했으�, 2025� 7� 28� 동부시간 00:01부� 효력� 발생합니�. 발행 주식 수는 � 4� 6,710� 주에� � 2,340� 주로 감소하며, 주식 보상, 워런� � 전환사채� 비례 조정됩니�. 분할 � 소수 주식은 발행하지 않고 현금으로 정산합니�. 이번 조치� 2025� 2� 주가가 미화 1.00달러 이하� 떨어� � NYSE 상장 요건� 회복하기 위한 것입니다. 거래 심볼은 CHPT� 유지되며, 새로� CUSIP은 15961R 303입니�.

투자자에 대� 주요 영향:

  • 주식 분할은 주당 가격을 즉시 상승시켜 NYSE 상장� 유지하는 � 도움� 되지�, 기본 펀더멘� 개선은 아닙니다.
  • 주식 � 감소� 주당 지�(EPS, 장부가�)� 기계적으� 증가시킬 � 있으�, 지� 비율은 변하지 않습니다.
  • CLO� 퇴임은 단기적인 승계 � 거버넌스 위험� 초래합니�.
  • 기업 기회 면제 붶결은 일부 주주가 거버넌스 수정안에 대� 우려� 표명했음� 시사합니�.

ChargePoint Holdings, Inc. (NYSE : CHPT) a déposé un formulaire 8-K couvrant les actions du conseil d'administration et de la société prises entre le 7 et le 9 juillet 2025.

Changement clé de personnel : Rebecca Chavez, Chief Legal Officer et Corporate Secretary, démissionnera à compter du 25 juillet 2025 pour poursuivre une autre opportunité.

Résultats de l'Assemblée Générale Annuelle 2025 (58,6 % de quorum) :

  • Quatre administrateurs de Classe II ont été réélus pour un mandat jusqu'en 2028.
  • PWC a été ratifiée en tant qu'auditeur indépendant pour l'exercice 2026.
  • Le vote consultatif « say-on-pay » a été approuvé (80,3 millions pour contre 15,2 millions contre).
  • Amendement sur le fractionnement inverse des actions approuvé (232,9 millions pour, 34,1 millions contre) permettant un ratio de fractionnement entre 1 pour 2 et 1 pour 30.
  • L'amendement sur la dérogation aux opportunités corporatives a édzé.
  • Autorisation de ajournement approuvée.

Fractionnement inverse des actions exécuté : Le 9 juillet 2025, le Comité de nomination et de gouvernance a fixé le ratio à 1 pour 20, effectif à 00h01 ET le 28 juillet 2025. Le nombre d'actions en circulation passera d'environ 467,1 millions à environ 23,4 millions ; les attributions d'actions, les bons de souscription et les billets convertibles seront ajustés proportionnellement. Aucune action fractionnaire ne sera émise ; un paiement en espèces sera effectué à la place. Cette mesure vise à retrouver la conformité avec le NYSE après être tombée en dessous du prix minimum de 1,00 USD en février 2025. Le symbole boursier reste CHPT ; nouveau CUSIP 15961R 303.

Implications importantes pour les investisseurs :

  • Le fractionnement devrait immédiatement augmenter le prix par action et préserver la cotation NYSE, mais il n'améliore pas les fondamentaux sous-jacents.
  • La réduction du nombre d'actions peut mécaniquement augmenter les indicateurs par action (BPA, valeur comptable) sans changer la propriété proportionnelle.
  • Le départ du CLO introduit un risque de succession et de gouvernance à court terme.
  • L'échec de la dérogation aux opportunités corporatives suggère certaines préoccupations des actionnaires concernant les amendements de gouvernance.

ChargePoint Holdings, Inc. (NYSE: CHPT) reichte ein 8-K ein, das Vorstandsbeschlüsse und unternehmerische Maßnahmen zwischen dem 7. und 9. Juli 2025 abdeckt.

Wichtige Personaländerung: Chief Legal Officer & Corporate Secretary Rebecca Chavez wird zum 25. Juli 2025 zurücktreten, um eine andere Gelegenheit wahrzunehmen.

Ergebnisse der Hauptversammlung 2025 (58,6 % Quorum):

  • Vier Class-II-Direktoren wurden bis 2028 wiedergewählt.
  • PWC als unabhängiger Abschlussprüfer für das Geschäftsjahr 2026 bestätigt.
  • Beratende „Say-on-Pay�-Abstimmung angenommen (80,3 Mio. dafür vs. 15,2 Mio. dagegen).
  • Änderung zur Umkehraktienzusammenlegung genehmigt (232,9 Mio. dafür, 34,1 Mio. dagegen), die eine Split-Quote zwischen 1:2 und 1:30 erlaubt.
  • Änderung zur Corporate Opportunity Waiver abgelehnt.
  • Vertagungsbefugnis genehmigt.

Umkehraktienzusammenlegung durchgeführt: Am 9. Juli 2025 legte der Nominierungs- und Governance-Ausschuss das Verhältnis auf 1:20 fest, wirksam ab 28. Juli 2025, 00:01 Uhr ET. Die ausstehenden Aktien reduzieren sich von ca. 467,1 Millionen auf ca. 23,4 Millionen; Aktienprämien, Warrants und Wandelanleihen werden proportional angepasst. Bruchstücke werden nicht ausgegeben; stattdessen wird Barzahlung geleistet. Die Maßnahme zielt darauf ab, die NYSE-Compliance wiederherzustellen, nachdem der Kurs im Februar 2025 unter die Mindestnotierung von 1,00 USD gefallen war. Das Handelssymbol bleibt CHPT; neue CUSIP 15961R 303.

Wesentliche Auswirkungen für Investoren:

  • Der Split sollte den Kurs sofort anheben und die NYSE-Notierung erhalten, verbessert jedoch nicht die zugrunde liegenden Fundamentaldaten.
  • Die Reduzierung der Aktienanzahl kann die Kennzahlen pro Aktie (EPS, Buchwert) mechanisch erhöhen, ohne die prozentuale Eigentümerschaft zu verändern.
  • Der Weggang des CLO bringt kurzfristige Nachfolge- und Governance-Risiken mit sich.
  • Die Ablehnung des Corporate Opportunity Waivers deutet auf Bedenken einiger Aktionäre hinsichtlich der Governance-Änderungen hin.
false 0001430306 0001430306 2025-07-09 2025-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): July 9, 2025

 

TONIX PHARMACEUTICALS HOLDING CORP. 

(Exact name of registrant as specified in its charter)

 

Nevada 001-36019 26-1434750
(State or Other Jurisdiction 
of Incorporation) 
(Commission 
File Number)
(IRS Employer 
Identification No.) 

 

26 Main Street, Chatham, New Jersey 07928

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (862) 799-8599

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock TNXP The NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On July 9, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced that full results from its confirmatory Phase 3 RESILIENT trial of its TNX-102 SL (cyclobenzaprine HCl sublingual tablets) product candidate for the management of fibromyalgia have been published online in the peer reviewed Pain Medicine, the official journal of the American Academy of Pain Medicine. A copy of the press release which discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference. A copy of the article is furnished hereto as Exhibit 99.02, and incorporated herein by reference.

 

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01. Other Events.

 

On July 9, 2025, the Company announced that full results from its confirmatory Phase 3 RESILIENT trial of TNX-102 SL have been published online in Pain Medicine in an article titled “Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual Cyclobenzaprine.

 

Forward- Looking Statements 

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  

Exhibit

No.

  Description.
    99.01   Press Release of the Company, dated July 9, 2025
    99.02   Pain Relief by Targeting Nonrestorative Sleep in Fibromyalgia: A Phase 3 Randomized Trial of Bedtime Sublingual Cyclobenzaprine
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  TONIX PHARMACEUTICALS HOLDING CORP.
   
Date: July 9, 2025 By: /s/ Bradley Saenger  
    Bradley Saenger
    Chief Financial Officer

 

 

FAQ

Why is ChargePoint (CHPT) executing a 1-for-20 reverse stock split?

The split is intended to lift CHPT’s price above US$1.00 and restore compliance with NYSE listing Rule 802.01C.

When will the CHPT reverse split take effect?

12:01 a.m. ET on July 28 2025; trading will begin on a split-adjusted basis the same day.

How many ChargePoint shares will be outstanding after the split?

Approximately 23.4 million shares, down from about 467 million before the split.

Did shareholders approve executive compensation at the 2025 meeting?

Yes. 80.3 million votes supported the advisory say-on-pay proposal; 15.2 million opposed.

Who is leaving ChargePoint’s executive team?

Chief Legal Officer & Corporate Secretary Rebecca Chavez will resign effective July 25 2025.

Was the Corporate Opportunity Waiver amendment approved?

No. It failed with 5.8 million votes against and 2.0 million abstentions.
Tonix Pharmaceut

NASDAQ:TNXP

TNXP Rankings

TNXP Latest News

TNXP Latest SEC Filings

TNXP Stock Data

274.42M
7.35M
3.32%
9.86%
Biotechnology
Pharmaceutical Preparations
United States
CHATHAM